According to the National Medical Products Administration (NMPA), three innovative drugs were approved for marketing in China in February 2026. These newly added entries to the NMPA approved drugs list cover moderate-to-severe plaque psoriasis, myelofibrosis,…
In May 2023, China’s National Medical Products Administration (NMPA) approved the first domestically developed generic version of olaparib tablets. Developed by Qilu Pharmaceutical, this olaparib product was officially approved on May 12 and subsequently launched…
Adebrelimab approval in China marks a significant milestone in the country’s oncology landscape. In 2023, China’s National Medical Products Administration (NMPA) approved adebrelimab injection (Airuili®) for use in combination with standard chemotherapy as a first-line…
As innovation in drug research and development continues to accelerate, the pharmaceutical industry is entering a new stage of evolution. By 2026, competition is no longer defined solely by the ability to innovate but increasingly…
In the era of precision oncology, an effective treatment strategy requires more than just a powerful therapeutic “weapon.” It also depends on a flexible “delivery system” and adaptable “tactics” tailored to different clinical scenarios. The…
(China, December 23, 2025) — Sunshine Guojian Pharmaceutical, a leading biopharmaceutical company in China, today announced that TPIAO approved for a new indication—its independently developed Class 1 innovative drug—by the National Medical Products Administration (NMPA).…
On January 6, 2026, BeiGene (Suzhou) Biotech Co., Ltd. (BeiGene) ‘s independently developed innovative drug Sonrotoclax tablets (trade name: Baiyueda®) were officially approved for market launch in China. The approved indications for sonrotoclax tablets in China…
On December 25, 2020, the National Medical Products Administration (NMPA) granted priority review and approval for orelabrutinib tablets (brand name: InnoCare®), a Class 1 innovative drug independently developed by Beijing InnoCare Pharma Technology Co., Ltd.…
Hong Kong DengYue Medicine News – October 30, 2025 – Lepu Biopharma Co., Ltd. (“Lepu Bio”) announced that its self-developed innovative antibody-drug conjugate (ADC)—Becotatug Vedotin for Injection (trade name: Meiyouheng®)—has been formally approved for marketing by the National…
For approximately 5.6 million patients worldwide living with progressive pulmonary fibrosis (PPF), every breath is accompanied by the relentless and irreversible scarring of their lungs. This is a fatal pulmonary disease, with nearly half of…
China’s breast cancer treatment landscape has reached a new milestone with the regulatory approval of the globally innovative antibody–drug conjugate Datopotamab Deruxtecan (Datroway). Official Approval: Defined Indication and Clinical Positioning On August 22, 2025, the…
The year 2025 marked a profound paradigm shift for China’s innovative drug industry. We witnessed the historic achievement of the “Dual Harvest for China Innovative Drugs.” ✨ The “Dual Harvest” signifies: 1️⃣ lies the scientific voice defining global…
